9f621704-2ece-4b25-be28-5fe14f71048d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INFLAMMATORY_RESPONSE+0.600
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- TNFA_SIGNALING_VIA_NFKB+0.600
- COMPLEMENT+0.500
- KRAS_SIGNALING_UP+0.500
- TGF_BETA_SIGNALING+0.500
Top 10 suppressed
- MYC_TARGETS_V2-0.700
- OXIDATIVE_PHOSPHORYLATION-0.600
- DNA_REPAIR-0.500
- MYC_TARGETS_V1-0.500
- E2F_TARGETS-0.300
- FATTY_ACID_METABOLISM-0.200
- GLYCOLYSIS-0.200
- SPERMATOGENESIS-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3277 | Med | Medulloblastoma | 0.934 |
| 2 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.930 |
| 3 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.929 |
| 4 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.924 |
| 5 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.920 |
| 6 | MDT-AP-2869 | Med | Medulloblastoma | 0.918 |
| 7 | MDT-AP-3156 | Med | Medulloblastoma | 0.917 |
| 8 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.915 |
| 9 | TCGA-CN-5373-01A-01R-1436-07 | — | — | 0.912 |
| 10 | MDT-AP-2111 | Med | Medulloblastoma | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.600 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.500 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |